A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic LymphomaXiao‐Peng Tian, Guo‐Wei Li, Juan Li et al.|Clinical Cancer Research|2020Cited by 40
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐<scp>BCMA CAR</scp> T‐cell‐based therapyYuekun Qi, Jiang Cao, Hujun Li et al.|American Journal of Hematology|2024Cited by 21
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Xin Du, Hui Zhou et al.|Advances in Therapy|2021Cited by 19
Supplementary Figure S12 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic LymphomaXiao-Peng Tian, Guo‐Wei Li, Ning Su et al.|Unknown|2023Cited by 0
Supplementary Figure S2 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic LymphomaXiao-Peng Tian, Guo‐Wei Li, Ning Su et al.|Unknown|2023Cited by 0